Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors

Kimura, Satoshi; Ohkawara, Hiroshi; Minakawa, Keiji; Fukatsu, Masahiko; Mori, Hirotaka; Takahashi, Hiroshi; Harada-Shirado, Kayo; Ohara, Yoshihiro; Takahashi, Nobuhisa; Mochizuki, Kazuhiro; Sano, Hideki; Nollet, Kenenth E; Ogawa, Kaoru; Ohto, Hitoshi; Kikuta, Atsushi; Ikeda, Kazuhiko; Ikezoe, Takayuki

doi:10.1016/j.transci.2020.102737

Cited by 9 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most international organizations and registries, including the National Marrow Donor Program (NMDP), recommend day 5 for collection initiation. However, recent scientific evidence suggests that there is no significant difference in terms of the collected dose or purity of the product between day 4 and day 5 collection [29,95,96]. Moreover, donors who collect on day 4 do not appear to have an increased risk of requiring a second collection procedure compared to those who start on day 5 [97].…”

Section: Timing and Tools For Stem Cell Collection Predictionmentioning

confidence: 99%

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Prisciandaro,

Santinelli,

Tomarchio

et al. 2024

Cells

View full text Add to dashboard Cite

Achieving successful hematopoietic stem cell transplantation (HSCT) relies on two fundamental pillars: effective mobilization and efficient collection through apheresis to attain the optimal graft dose. These cornerstones pave the way for enhanced patient outcomes. The primary challenges encountered by the clinical unit and collection facility within a transplant program encompass augmenting mobilization efficiency to optimize the harvest of target cell populations, implementing robust monitoring and predictive strategies for mobilization, streamlining the apheresis procedure to minimize collection duration while ensuring adequate yield, prioritizing patient comfort by reducing the overall collection time, guaranteeing the quality and purity of stem cell products to optimize graft function and transplant success, and facilitating seamless coordination between diverse entities involved in the HSCT process. In this review, we aim to address key questions and provide insights into the critical aspects of mobilizing and collecting hematopoietic stem cells for transplantation purposes.

show abstract

Section: Timing and Tools For Stem Cell Collection Predictionmentioning

confidence: 99%

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Prisciandaro,

Santinelli,

Tomarchio

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…Teipel et al, in a retrospective study of 7,216 HDs, found that female sex, older age, smoking, elevated lactate dehydrogenase, higher lymphocyte count and large unstained cell count were associated with poor CD34+ cell count after 4 days of mobilization with G-CSF [17]. Kimura et al analysed a series of 109 allogeneic donors and 181 leucocytapheresis procedures, and they found that donors' cytomegalovirus (CMV) seronegative status and male gender yielded better results [46]. In the same study, the best yields happened in donors between 20 and 30 years old, with yields decreasing in donors older than 40 years.…”

Section: How Is Plerixafor Used? Dosing and Administrationmentioning

confidence: 99%

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

et al. 2021

View full text Add to dashboard Cite

Increased transplant activity calls for improved stem cell collection, especially when peripheral blood is the preferred source of haematopoietic progenitor cells (HPCs).Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4-CXCL12-supported HPC retention. Plerixafor is given with granulocyte colony-stimulating factor (G-CSF) to help harvest autologous CD34+ cells for transplantation when mobilization with G-CSF fails. Mobilization protocols with the same doses of plerixafor and G-CSF have been used off-label in healthy allogeneic donors, with equal success and scarce side effects, both in adult and paediatric patients.Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G-CSF might lead to harvesting distinct cellular populations conferring improved engraftment properties and increased survival. Those characteristics might make plerixafor an especially attractive mobilization agent, particularly for non-related donations. However, available data are limited, and long-term follow-up is needed to clarify the best scenario for using plerixafor with or without G-CSF in healthy donors.In this review, we will summarize the evidence supporting this practice, highlighting the practical aspects and providing clues for an expanded use of plerixafor.

show abstract

“…stimulating factors(G-CSF)for 4 to 6 consecutive days is necessary. [3][4][5][6] In Japan, more than 80% of donors have been hospitalized during the period of G-CSF administration. 7,8 Our policy has been to administer G-CSF for the mobilization of PBSC on an outpatient basis.…”

Section: Case Reportmentioning

confidence: 99%

Safety and efficacy of outpatient-based administration of granulocyte colony-stimulating factor in collection of allogeneic peripheral blood stem cells: 10 years of single-center experience in 86 donors

Osaki

Morishige

Nakamura

et al. 2021

Journal of Hematopoietic Cell Transplantation

View full text Add to dashboard Cite

Our policy has been to administer granulocyte colony-stimulating factors (G-CSF) for the mobilization of peripheral blood stem cells (PBSC) on an outpatient basis. We evaluated the safety of G-CSF-administered PBSC donation in outpatients and inpatients. Subjects：PBSC donations from 86 healthy donors(78 related, 8 unrelated) between January 2011 and December 2019 were included; 74 donors were administered G-CSF as outpatients, and 12 while under hospitalization. Evaluation of the length of hospital stay(LOHS) ：LOHS of the donors who were administered G-CSF as outpatients(median, 2 days; range, 1 to 4 days)was significantly shorter than that of the inpatient donors(median, 4.5; range, 4 to 5) (P＜0.0001) . Adverse events of G-CSF administration：There was no significant difference in the incidence of adverse events related to G-CSF administration between the donors who were administered G-CSF as outpatients and those as inpatients(P＝0.1786) . Efficacy of PBSC mobilization：Most donors donated sufficient PBSC(median CD34 ＋ ×10 6 cells／kg recipient body weight, 5.65) . There was no significant difference in the number of collected CD34 ＋ cells between the two groups(P＝0.6671) . Conclusion：Outpatient-based administration of G-CSF for PBSC mobilization was feasible without compromising donor safety or PBSC donation efficacy.

show abstract

Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors

Cited by 9 publications

References 23 publications

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Stem Cells Collection and Mobilization in Adult Autologous/Allogeneic Transplantation: Critical Points and Future Challenges

Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

Safety and efficacy of outpatient-based administration of granulocyte colony-stimulating factor in collection of allogeneic peripheral blood stem cells: 10 years of single-center experience in 86 donors

Contact Info

Product

Resources

About